Whalen Wealth Management Inc. Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Whalen Wealth Management Inc. bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 1,933 shares of the company’s stock, valued at approximately $264,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of NBIX. State Street Corp increased its stake in Neurocrine Biosciences by 11.7% in the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after purchasing an additional 539,936 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in Neurocrine Biosciences by 639.6% during the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares in the last quarter. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Braidwell LP increased its position in shares of Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after buying an additional 158,665 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Neurocrine Biosciences by 45.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 472,929 shares of the company’s stock worth $65,097,000 after buying an additional 147,907 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Up 0.6 %

NBIX stock opened at $146.76 on Thursday. The company has a market cap of $14.86 billion, a price-to-earnings ratio of 39.35 and a beta of 0.33. The business has a fifty day simple moving average of $132.54 and a 200-day simple moving average of $131.19. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 1,091 shares of the business’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,694 shares of company stock worth $9,676,730 over the last three months. 4.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NBIX. BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Raymond James reiterated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 16th. Finally, William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $164.81.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.